(060) Comparison of Prescribing and Google Trends Between Bremelanotide (Vyleesi®) and Flibanserin (Addyi®) for Female Hypoactive Sexual Desire Disorder

Abstract Introduction Hypoactive sexual desire disorder (HSDD) affects an estimated 10% of adult women of all ages, causing distress and decreased quality of life. In the United States two drugs have been approved to treat HSDD in premenopausal women: bremelanotide (Vyleesi®), which was approved in 2019, and flibanserin (Addyi®), approved in 2015. Objective Herein we sought to compare national prescribing data for these medications, and Google trends to identify terminology commonly used by patients seeking medical information. Methods We contacted the pharmaceutical companies for Vyleesi® (Cosette Pharmaceuticals, Bridgewater, NJ) and Addyi® (Sprout Pharmaceuticals, Raleigh, NC) and obtained current deidentified prescriber data. Google trends were queried to analyze common search terms for HSDD from January 2019 to October 2025. Results Prescribing trends are similar between the two drugs (Table 1). Average patient age is 45.5 for Vyleesi and 43.5 for Addyi. Patients are almost exclusively female; interestingly, 4% of Vyleesi and 2% of Addyi prescriptions were to male patients. Most patients are reimbursed with commercial insurance though more patients prescribed Vyleesi have this coverage compared to Addyi (81% versus 50%). Obstetricians and gynecologists are the most common prescribers for both at ~40%; urologists made up 2-4% of prescribers. Google trends analysis revealed that “hypoactive sexual desire disorder,” “female low libido” and treatments were not commonly searched. “Female Viagra” was the most popular search term, though declined significantly after 2019. Conclusions Vyleesi and Addyi have similar prescribing patterns. Google trends analysis revealed that “Female Viagra” was the most common term, though overall search activity was low. Patients may be receiving education from other sources. Further research should be conducted on optimal patient education. Disclosure No.